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3168, Australia; Department of Biochemistry and Molecular Biology (C.M.S.), Monash University,
Clayton, Victoria 3800, Australia; and Robinson Institute (L.J.R., R.B.G.), Research Centre for
Reproductive Health, School of Paediatrics and Reproductive Health, University of Adelaide, Adelaid,
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Growth differentiation factor 9 (GDF9) controls granulosa cell growth and differentiation during
early ovarian folliculogenesis and regulates cumulus cell function and ovulation rate in the later
stages of this process. Similar to other TGF- superfamily ligands, GDF9 is secreted from the oocyte
in a noncovalent complex with its prodomain. In this study, we show that prodomain interactions
differentially regulate the activity of GDF9 across species, such that murine (m) GDF9 is secreted in
an active form, whereas human (h) GDF9 is latent. To understand this distinction, we used site-
directed mutagenesis to introduce nonconserved mGDF9 residues into the pro- and mature do-
mains of hGDF9. Activity-based screens of the resultant mutants indicated that a single mature
domain residue (Gly391) confers latency to hGDF9. Gly391 forms part of the type I receptor binding
site on hGDF9, and this residue is present in all species except mouse, rat, hamster, galago, and
possum, inwhich it is substitutedwith an arginine. In an adrenocortical cell luciferase assay, hGDF9
(Gly391Arg) had similar activity to mGDF9 (EC50 55 ng/ml vs. 28 ng/ml, respectively), whereas wild-
type hGDF9was inactive. hGDF9 (Gly391Arg) was also a potent stimulator of murine granulosa cell
proliferation (EC50 52 ng/ml). An arginine at position 391 increases the affinity of GDF9 for its
signaling receptors, enabling it to be secreted in an active form. This important species difference
in theactivation statusofGDF9may contribute to thevariationobserved in folliculardevelopment,
ovulation rate, and fecundity between mammals. (Endocrinology 153: 1301–1310, 2012)
Oocyte-derived growth differentiation factor 9(GDF9), a member of the TGF- superfamily, is es-
sential for mammalian ovarian folliculogenesis (1). GDF9
controls both early follicular maturation and the number
of ovulating follicles in each estrus cycle (2). Female mice
deficient in GDF9 have no antral follicles, no ovulations,
andnopregnancies.Organogenesis of theGDF9/ovary
is morphologically normal with large numbers of primor-
dial follicles, many of which advance to the primary type
3b stage (i.e. the point at which the oocyte is fully grown
with a single layer of cuboidal granulosa cells) (1). In the
absence of GDF9, however, folliculogenesis does not
progress beyond this point. The arrested follicles have ab-
normal granulosa cells and they fail to acquire a theca
layer, indicating thatGDF9exerts paracrineactionson the
surrounding somatic cells (1). The block in normal follic-
ular growth is followed by degeneration of the oocyte and
the formation of abnormal nests of luteinizing granulosa
cells (1).
Studies in sheep have identified two point mutations in
GDF9 that result in sterility. The Ser395Phe mutation in
Belclare sheep (3) and the Ser427Arg mutation in Thoka
sheep (4) arepredicted todisrupt type I and type II receptor
interactions, respectively, and ewes homozygous for these
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inactivating mutations are infertile with ovaries that re-
semble GDF9 / mice. Interestingly, reduced GDF9 ac-
tivity in ewes heterozygous for these mutations may in-
crease the FSH sensitivity of secondary follicles, leading to
increased numbers of antral follicles that undergo preco-
cious maturation and ovulate at smaller stages (3–5).
Thus, a reduction in GDF9 activity is actually associated
with increased fecundity, promoting the concept of adose-
dependent effect of GDF9 on ovulation rate.
The vital importance of GDF9 in maintaining female re-
productive homeostasis implies that any alteration in this
gene might lead to infertility and ovarian pathology. Thus,
screening for mutations in GDF9 in womenwith premature
ovarian failure (i.e. women under 40 yr of age who experi-
ence approximately 6 months of amenorrhea and elevated
serum FSH levels) identified several missense mutations not
found incontrolwomen(6–8).Mutations in theGDF9gene
havealsobeen identified in themothersofdizygotic twins (9,
10) and in women with polycystic ovary syndrome (11), a
common condition (in 5–10% of women) of ovarian dys-
function linked to aberrant folliculogenesis (12).
Although GDF9 is crucial for the maintenance of fe-
male reproductive homeostasis in murine, ovine, and hu-
man systems, recent studieshave indicated that theactivity
of GDF9 is differentially regulated across species (13, 14).
Similar to other TGF- ligands, GDF9 is synthesized as a
precursor molecule consisting of an N-terminal prodo-
main and a C-terminal mature domain (15). During syn-
thesis, the prodomain interacts noncovalently with ma-
ture GDF9, maintaining the molecule in a conformation
competent for dimerization (13). Dimeric precursors are
cleaved by proprotein convertases and GDF9 is secreted
from the oocyte noncovalently associated with its prodo-
main. The continued presence of the prodomain does not
suppress the biological activity of murine GDF9, which can
directly regulate the growth and differentiation of granulosa
cells bybinding to cell surface receptors (13).HumanGDF9,
incontrast, is secreted ina latentcomplexwith itsprodomain
(13) and presumably requires activation before receptor
binding. This is the first observed species difference in the
activation status of aTGF- ligand, and itmay contribute to
the variation observed in follicular development, ovulation
rate, and fecundity between mammals.
In this study, we have characterized the molecular
interactions that confer latency to human (h) GDF9.
Using site-directed mutagenesis, we introduced non-
conserved murine (m) GDF9 residues into the pro- and
mature domains of hGDF9, with the aim to activate this
latent growth factor. Of the mutants generated, only
hGDF9 (Gly391Arg) was active in both an adrenocor-
tical cell luciferase assay and a mouse granulosa cell
proliferation assay. These findings indicate that Gly391
is responsible for maintaining hGDF9 in a latent com-
plex with its prodomain.
Materials and Methods
Reagents
mGDF9 and the polyhistidine monoclonal antibody were
purchased from R&D Systems (Minneapolis, MN). GDF9 an-
tibody (mAb53)waspurchased fromAbDSerotec (Oxford,UK),
whereas horseradish peroxidase-conjugated antimouse IgG was
from GE Healthcare (Buckinghamshire, UK). Lumilight chemi-
luminesence Western blotting substrate was obtained from
Roche (Basel, Switzerland), BioXact short DNA polymerase
from Bioline (Taunton, MA), PCR/plasmid purification kits
from Promega (Madison, WI), and DMEM, DMEM:F12, Opti-
MEM, and SeeBlue Plus2 from Invitrogen (Carlsbad, CA).
Production and purification of recombinant GDF9
The development of a stable human embryonic kidney 293
(HEK-293) T cell line expressing mGDF9 has been described
previously (16). To produce large amounts of hGDF9, we gen-
erated a stableHEK-293E cell line. Briefly, the hGDF9 genewith
anN-terminalHis-tagwas generated by overlap PCRand cloned
into theXbaI and Sse8387I sites of pAPEX3P. HEK-293 E cells,
plated at 8  105 cells in six-well plates, were transfected with
hGDF9/pAPEX3P (5g) using polyethyleneimine (1mg/ml; Sig-
ma-Aldrich, St. Louis, MO). Cells were incubated for 24 h in
culture medium [DMEM/10% fetal calf serum (FCS)/50 mM
HEPES/Pen-Strep/250 g/ml geneticin] before the addition of
puromycin (2 g/ml; Sigma-Aldrich). Successfully transfected
cells, which expressed resistance to puromycin, were expanded
forming a stable cell population (referred to as 293E hGDF9
cells). To produce hGDF9, 293E-hGDF9 cells were transferred
into production media [DMEM:F12 medium containing L-glu-
tamine, 0.02% BSA, and 0.01% heparin (Sigma-Aldrich)] and
cultured for 4 d. The resultant conditioned medium was centri-
fuged, filtered througha0.45-mfilter, concentrated (Centricon
Plus-70; Millipore, Billerica, MA), and resuspended in binding
buffer (50 mM phosphate buffer; 0.5M NaCl, pH 8.0). The
concentrated media were then subjected to immobilized metal
affinity chromatography (IMAC) usingNi-NTAAgarose (Invit-
rogen) prepacked in an HR10/10 column (GEHealthcare). His-
tagged hGDF9 was eluted from the Ni-NTA Agarose using elu-
tion buffer (50 mM phosphate buffer; 0.5M NaCl; 0.5M
imidazole, pH 8.0) before final purification by reverse-phase
HPLC.Todetermine the purity andmass of hGDF9after the two
chromatography steps, protein fractions (reduced with 5%
-mercaptoethanol) were fractionated on 10% SDS-PAGE gels
and either silver stained or subjected toWestern blot. After elec-
trophoresis, samples were transferred onto enhanced chemilu-
minescence Hybond membranes (GE Healthcare) and probed
with the GDF9-specific monoclonal antibody (mAb)-53 (1:
5,000) (17) or anti-His primary antibody (1:1,000) and a sec-
ondary antibody, horseradish peroxidase-conjugated antimouse
IgG (1:10,000). Immunoreactive proteins were detected using
Lumilight chemiluminesence reagents (Roche). Mass estimates
for hGDF9 throughout the purification were determined by
Western blot using recombinant mGDF9 (R&D Systems) as a
reference.
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Production of hGDF9 point mutants
Point mutations in the pro- and mature regions of hGDF9
were introduced using the QuikChange Lightning site-directed
mutagenesis kit (Stratagene, La Jolla, CA). pCDNA3.1 (Invit-
rogen) vectors containing full-lengthhGDF9cDNAserved as the
template in these reactions. For each construct, the mutated re-
gion was confirmed by DNA sequencing. Wild-type and mutant
hGDF9 proteins were produced by transient transfection in
HEK-293 T cells using Lipofectamine 2000. Briefly, the HEK-
293 T cells were plated at 9  105 cells/well in a six-well plate.
Wild-type or mutant hGDF9 DNA (5 g) was combined with
Lipofectamine 2000 (Invitrogen) according to the manufactur-
er’s instructions. After 20 min incubation, DNA-Lipofectamine
complexes were added directly to the plated cells and incubated
in DMEM/10% FCSmedium for 24 h at 37 C in 5%CO2. After
24 h, the medium was removed and replaced with production
media and incubated for a further 48 h at 37 C in 5% CO2. The
amount of hGDF9 variants in the conditioned medium was de-
termined by Western blotting, as described above.
Generation of a mouse/human GDF9 chimera
Totestwhetherdifferenceswithin theprodomainsofmouseand
hGDF9 contributed to their bioactivity, we generated amouse/hu-
man GDF9 chimera (mhGDF9). mhGDF9 was engineered by fus-
ing the prodomain of mGDF9 (residues 1–306) to the mature do-
main of hGDF9 (residues 320–454). mhGDF9 was generated by
overlapping PCR (mGDF9 prodomain sense primer: 5-caccatcat-
catcatcaccacgaagaatcccagagtggagccagtg-3; antisense primer: 5-
tcgacggcgccggggagatc-3; hGDF9mature domain sense primer: 5-
gatctccccggcgccgtcgaggtcaggaaactgtcagttctg-3; antisense primer:
5-atcgggatccttaacgacaggtgcactttg-3) and
cloned intotheBamHIandHindIII sitesof the
pCDNA3.1()vector (Invitrogen).mhGDF9
was produced by transient transfection in
HEK-293 T cells using Lipofectamine 2000
(Invitrogen), as described above.
In vitro bioassay
Wild-type and mutant hGDF9 were com-
pared with mGDF9 for their ability to stim-
ulate a luciferase response in a mouse adre-
nocortical cell line (AC) (18) or in a human
granulosa cell line (KGN). Briefly, AC or
KGN cells were plated in 48-well plates at
114,000 cells/well or 40,000 cells/well, re-
spectively. After 24 h incubation, cells were
transfected with an activin responsive lu-
ciferase reporter construct (pGRAS) using Li-
pofectamine 2000 (Invitrogen) according to
the manufacturer’s protocol. The cells were
washed 24 h after transfectionwith complete
medium (DMEM/10% FCS) and treated for
16 h with either mGDF9 or hGDF9 variants
(7.8–500ng/ml). Themediumwas aspirated,
and the cellswere solubilized in solubilization
buffer ([25mMglycylglycine (pH7.8), 15mM
MgSO4, 4mMEGTA,1%TritonX-100, and
1 mM dithiothreitol], and luciferase reporter
activity was measured.
Receptor binding studies
Carrier-free mGDF9 (1 g; R&D Sys-
tems) in 15 l 0.5 M sodium phosphate buf-
fer, pH7.5,was labeledwith Iodine-125 (Per-
kin Elmer, Boston,MA). The stability of 125I-
GDF9 was limited, with all binding assays
performed on the day of iodination. AC cells
were plated at 2 105 cells/well in DMEM/
10% FCS in 24-well plates coated with poly-
D-lysine. The following day, the cells were
washed in a binding buffer (DMEM/0.1%
BSA) and incubated for 4 h at room temper-
ature with 125I-GDF9 (40,000 cpm/well) to-
gether with increasing concentrations of
GDF9 variants (0.03–20 nM). The cells were
FIG. 1. Human GDF9 is secreted in a latent complex with its prodomain. A, Adrenocortical
cells transfected with a Smad2/3-responsive luciferase reporter were stimulated with
increasing concentrations (7.8–1000 ng/ml) of either mGDF9- (F) or hGDF9 (E)-conditioned
medium. Luciferase activity was measured as described in Materials and Methods. B (inset),
Western blot analysis of hGDF9 in conditioned medium and after IMAC purification, using
mature domain (mAb53) or prodomain (anti-His) antibodies. B, Adrenocortical cells
transfected with a Smad2/3-responsive luciferase reporter were stimulated with increasing
concentrations (7.8–500 ng/ml) of IMAC-purified hGDF9 (E). C, hGDF9 eluted from the
IMAC column was further purified by RP-HPLC using a Vydac Jupiter column (250  4.6 mm,
5 m particle size) on a gradient of 20–70% acetonitrile in 0.1% heptafluorobutyric acid at 1
ml/min over 90 min. HPLC fractions 64–69 were analyzed by SDS-PAGE and Western blot for
the presence of the pro- and mature domains of hGDF9 (inset), and fractions 64–65
(containing only mature hGDF9) were pooled. D, Adrenocortical cells transfected with a
Smad2/3-responsive luciferase reporter were stimulated with increasing concentrations (7.8–
250 ng/ml) of HPLC-purified mature hGDF9 (E). For each assay, the values are the means 
SD from two representative experiments.
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washed in cold 10 mM PBS (pH 7.4) and solubilized in 1% Triton
X-100.Radioactivitywasmeasuredusinga-counter.Thebinding
data were analyzed using the Prism program (version 5.0; Graph-
Pad Software Inc., San Diego, CA) and by Scatchard analysis.
Murine granulosa cell proliferation assay
Mice were maintained in accordance with the Australian Code
of Practice for Care andUse of Animals for Scientific Purposes and
with the approval of the Adelaide University Animal Ethics Com-
mittee. This mitogen bioassay was performed as previously de-
scribed (17, 19, 20). In brief, mural granulosa cells were recovered
from21- to26-d-old129/SVmice, 44–46hafter administrationof
5 IU of equine chorionic gonadotropin (5 IU; Folligon; Intervet,
Castle Hill, Australia). After recovery, mural granulosa cells were
washed in B-TCM-199 medium with supplements (19). Assays
were conducted with 25,000 granulosa cells per well in a 96-well
plate (Falcon; BectonDickinson, Franklin Lakes,NJ) in a final vol-
ume of 125 l. Cells were cultured in the presence of increasing
concentrations (3.9–500 ng/ml) of wild-type or mutant hGDF9
(recombinant mGDF9 was included as a positive control) in an
atmosphere of 37 C, 96% humidity in 5% CO2 in air for 18 h,
followed by a further 6-h pulse of 15.4 kBq [3H]thymidine (MP
Biomedicals, Solon, OH) under the same conditions. After the cul-
ture, mural granulosa cells were harvested, and the incorporated
[3H]thymidine was quantified using a scintillation counter as an
indicator of the proportion of cells in S phase, hence providing an
indication of the level of mural granulosa cell DNA synthesis and
proliferation. Each treatment was performed in duplicate and the
experiment repeated three times.
Results
Human GDF9 is secreted in a latent complex with
its prodomain
Previous studies have suggested thatmGDF9 is secreted
in an active form, whereas hGDF9 is latent (13). To con-
firm this, we assessed the ability of conditioned medium
from mGDF9 or hGDF9 expressing cells to activate a
phosphorylated mothers against decapentaplegic (Smad)-
2/3-responsive luciferase reporter (pGRAS) in a murine
adrenocortical cell line (18). Treatment of cells with
mGDF9resulted in adose-dependent increase in luciferase
activity (EC50 28ng/ml) (Fig. 1A). In contrast, hGDF9was
inactive at all doses tested (Fig. 1A).The lackof bioactivity
of hGDF9 was not due to defective production or pro-
cessing of the precursor molecule (Fig. 1B, lane 2, inset).
For some other TGF- ligands (TGF-1, -2, -3, myo-
statin, and GDF11), latency is conferred by high-affinity
interactions with their prodomains. The placement of a
His6 tag at the N terminus of the hGDF9 prodomain en-
abled us to use Ni2 based IMAC chromatography to
show that hGDF9was secreted in a latent complexwith its
prodomain (Fig. 1B and lane 3, inset). mGDF9 was also
secreted noncovalently associated with its prodomain
(Fig. 1B, lane 1, inset); however, the affinity of this inter-
actionwas insufficient to suppress biological activity. The
separation of mature hGDF9 from its prodomain by re-
versed-phase HPLC (RP-HPLC) (Fig. 1C) activated the
growth factor (Fig. 1D), indicating that the prodomain
plays a role in conferring latency to hGDF9.
The human GDF9 prodomain limits growth factor
expression
The prodomains of mouse and human GDF9 share
64%amino acid identity,whereas themature domains are
90%identical (Fig. 2). Basedon this analysis,wepredicted
that differences in the prodomains of mouse and human
GDF9 would determine the biological activity of the ma-
FIG. 2. Sequence alignment of mouse and human GDF9. The pro- (italics) and mature domains of mouse and human GDF9 were aligned using
ClustalW (Conway Institute, University College Dublin, Ireland). Secondary structure elements (-sheets and -helices) as determined by
QuickPhyre (Quick Protein Homology/analogy Recognition Engine, Structural Bioinformatics Group, Imperial College, London, UK) are depicted
above the sequences. Nonconserved hGDF9 residues in the 1-helix of the prodomain and throughout the mature domain predicted to influence
growth factor expression and activity are indicated (shaded gray). In this study, these hGDF9 residues were substituted for the corresponding
residues from mGDF9.
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ture growth factors. This concept was supported by stud-
ies showing that prodomains coordinate the formation
and stability of other latent TGF- complexes (21–24).
Therefore, we generated a mhGDF9 chimera by linking
the prodomain of mGDF9 (residues 1–306) to the mature
domain of hGDF9 (residues 320–454) (Fig. 3A). Expres-
sion of the mhGDF9 chimera was 10-fold higher than
wild-type hGDF9 (Fig. 3B, inset); however, activity was
not restored (Fig. 3B). To identify the regions of the
mGDF9 prodomain that contributed to increased expres-
sion of hGDF9, we referred to the recent crystal structure
of TGF-1 bound to its prodomain (25). In this structure,
residues within the N-terminal -helix (1) of the prodo-
mainmediate high-affinity interactionswithmature TGF-
1. Major differences exist within the 1-helix of mouse
and human GDF9 (Fig. 2). We substituted eight hGDF9
residues through this region for the corresponding resi-
dues frommGDF9, either alone or in combination. Of the
single- or double-point mutants generated, hGDF9
(Ala59Ser) andhGDF9(Ala64Pro)were expressedat3-fold
elevated levels comparedwithwild-type hGDF9 (Fig. 3C).
More strikingly, when all eight mGDF9 1-helix residues
were incorporated into hGDF9 (termed hGDF9 1-sub-
stitution) expression was increased 8-fold (Fig. 3C). To-
gether, these results indicate that specific residues within
the prodomain of hGDF9 limit mature growth factor ex-
pression; however, they do not confer latency.
A single mature domain residue confers latency to
hGDF9
The mature domains of mouse and human GDF9 are
90% identical, with most differences occurring at the disor-
deredNterminusorbeingconservative innature (Fig.2).We
substituted five nonconserved hGDF9 mature domain resi-
dues for the corresponding residues from mGDF9 (Fig. 2)
and assessed their effects on expression and biological activ-
ity. Of the five mutants tested (Leu328Ala, Pro334Thr,
Gly391Arg, Ser412Pro, and Ala422Gly) all expressed at levels
comparable with wild-type hGDF9, except Ala422Gly,
which was significantly reduced (Fig. 4A, inset). Similar to
wild-type hGDF9, the Leu328Ala, Pro334Thr, and Ser412Pro
variants were inactive in an adrenocortical cell luciferase as-
say (Fig. 4A). In contrast, hGDF9 (Gly391Arg)-conditioned
medium induced a dose-dependent increase in luciferase ac-
tivity (Fig. 4, A and B). Similar to wild-type hGDF9, the
Gly391Arg variant was secreted noncovalently associated
with its prodomain (data not shown); however, the affinity
of this interactionwasnotstrongenoughto inhibitbiological
activity (Fig. 4C). In amore physiologically relevant system,
hGDF9 (Gly391Arg) also stimulated a luciferase response in
the human KGN granulosa cell line (Fig. 4D).
hGDF9 (Gly391Arg) has higher affinity for its
signaling receptors than wild-type hGDF9
We reasoned that hGDF9 remains associated with its
prodomain in a latent complex because it has intrinsically
low affinity for its signaling receptors. Indeed, when we
separatedwild-type andmutant hGDF9 from their prodo-
mains by RP-HPLC, isolated mature hGDF9 (Gly391Arg)
was 8-fold more potent than the corresponding mature
region of wild-type hGDF9 (Fig. 5A), suggesting that a
substituted arginine at position 391 significantly increases
FIG. 3. Specific residues within the prodomain of hGDF9 limit mature
growth factor expression but do not confer latency. A, The prodomain
(residues 1–306) of mGDF9 was fused to the mature domain (residues
320–454) of hGDF9 to generate a mhGDF9 chimera. B, Adrenocortical
cells transfected with a Smad2/3-responsive luciferase reporter were
stimulated with increasing concentrations (7.8–500 ng/ml) of either
mhGDF9- (F) or hGDF9 (E)-conditioned medium. Luciferase activity
was measured as described in Materials and Methods. B (inset), The
expression of the mhGDF9 chimera, relative to hGDF9, was
determined by Western blot using the mature domain antibody
(mAb53). C, To identify the regions of the mGDF9 prodomain that
contributed to increased expression of hGDF9, residues in the 1-helix
of hGDF9 were substituted with the corresponding residues from
mGDF9, and effects on growth factor expression were determined by
Western blot analysis.
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the affinity of hGDF9 for its signaling receptors. To test
this, we determined the ability of mature hGDF9 variants
to block the binding of 125I-mGDF9 to its receptors on the
surface of AC cells (Fig. 5B). In this assay, hGDF9
(Gly391Arg) displayed a significantly higher affinity for its
signaling receptors (Kd 0.4 nM) than wild-type hGDF9
(Kd1nM) (Fig. 5C).Gly
391 formspart of the predicted type
I receptor binding site onmature hGDF9 (26, 27), and this
residue is present in all species exceptmouse, rat, hamster,
greater galago, and possum, inwhich it is substitutedwith
an arginine (Fig. 6). To determine the requirement for an
arginine at position 391 to activate hGDF9, we generated
two other hGDF9 variants, Gly391Leu and Gly391Ala. Al-
though expressed, both these mutants were inactive in the
adrenocortical cell luciferase assay (data not shown).
Thus, the bioactivity of GDF9 across species is dependent
on the nature of the amino acid at position 391.
hGDF9 (Gly391Arg) is a potent stimulator of
granulosa cell proliferation
Previous studies have shown that mGDF9 is a potent
oocyte-secreted granulosa cell mitogen (17, 20). In these
experiments we assessed the effect of hGDF9 variants on
murine granulosa cell proliferation. Wild-type hGDF9
and hGDF9 (Gly391Arg), purified via the His-tag within
their prodomains, were added to mural granulosa cells in
culture. Treatment of cells with hGDF9 (Gly391Arg) led to
a potent, dose-dependent stimulation of granulosa cell
DNA synthesis (EC50 55 ng/ml), as assessed by [
3H]thy-
midine incorporation (Fig. 7). Wild-type hGDF9, in con-
FIG. 4. A single mature domain residue confers latency to hGDF9. Selected mature domain residues of hGDF9 were substituted with the
corresponding residues from mGDF9, and the effects on growth factor expression and activity (100 ng/ml) were determined by Western blot (A,
inset) and in an adrenocortical cell luciferase assay (A). Adrenocortical cells transfected with a Smad2/3-responsive luciferase reporter were
stimulated with the indicated concentrations of hGDF9 (E) or hGDF9 (Gly391Arg) (F) in conditioned medium (B) or after IMAC purification (C).
hGDF9 (Gly391Arg) (F) also induced a luciferase response in the KGN cells transfected with a Smad2/3-responsive luciferase reporter (D). ND, Not
determined.
1306 Simpson et al. Latent Human GDF9 Endocrinology, March 2012, 153(3):1301–1310
trast, had no effect on granulosa cell proliferation.
Thus, a glycine at position 391 prevents hGDF9 from
directly mediating an important physiological function.
Interestingly, the extent of granulosa cell proliferation
in response to hGDF9 (Gly391Arg) was 4.5-fold lower
than that observed with recombinant mGDF9 (EC50 12
ng/ml) (Fig. 7).
Discussion
Themechanism of ovarian folliculogenesis in mammals is
reasonably well understood, involving a complex ex-
change of endocrine signals between the pituitary gland
and the ovary and the actions of autocrine and paracrine
factors secreted by the oocyte and its surrounding somatic
cells (28–30). GDF9 is one of the most important oocyte-
derived factors that regulate folliculogenesis, controlling
multiple aspects of this process, including granulosa cell
growth and differentiation (1, 31, 32). Studies in sheep
have also shown that GDF9, together with the related
TGF- ligand, bonemorphogenetic protein (BMP)15, is a
primary determinant of ovulation rate within species (i.e.
the number of mature oocytes released during one repro-
ductive cycle) (5, 29, 33). What has been less clear is
whether GDF9, given its high evolutionary conservation,
could contribute to the marked differences in ovulation
FIG. 5. hGDF9 (Gly391Arg) has high affinity for its signaling receptors.
A, Adrenocortical cells transfected with a Smad2/3-responsive
luciferase reporter were stimulated with the indicated concentrations
of HPLC-purified hGDF9 (E) or hGDF9 (Gly391Arg) (F). B, GDF9-
responsive AC cells were subjected to competition binding as
described in Materials and Methods. Displacement curves for HPLC-
purified hGDF9 (E) or hGDF9 (Gly391Arg) (F) are shown. The amount
of bound 125I-mGDF9 was determined in triplicate for each
experiment, and the values are the mean  SD. C, Scatchard plots of
hGDF9 (E) or hGDF9 (Gly391Arg) (F) binding to AC cells are shown.
FIG. 6. Sequence alignment of GDF9 across species. GDF9 sequences
were obtained from the UniProt database (www.uniprot.org/) and the
prehelix loop region was aligned using ClustalW. Note that Gly391 in
hGDF9 is conserved in all species except for mouse, rat, hamster,
greater galago, and possum, in which it is substituted with an arginine.
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rate between species. In this study, we have identified spe-
cific residues in the pro- and mature domains of hGDF9
that limit growth factor expression andactivity, relative to
mGDF9. These adaptations may contribute to the varia-
tion observed in ovulation rate and fecundity between
mammals.
The recent elucidation of the pro-TGF-1 crystal struc-
ture (25) provides some insights into why mouse and hu-
man GDF9 are expressed differently and have disparate
bioactivities.Within this structure, described as a straight-
jacket, the two prodomains form the neck, shoulders, and
upper arms and connect at the elbows to the crossed fore-
arms formed by the two TGF-1 monomers (25). Prodo-
main dimerization occurs between the eighth and ninth
-strands and links the prodomains in a bowtie at the
neck. Residues within the 1- and 2-helices and the in-
tervening latency lasso of the prodomains encircle the fin-
gers of each TGF-1 monomer and are likely to be im-
portant in directing the folding of the growth factor
domain (25). Significant differences exist in the prodo-
main 1-helices of mouse and human GDF9, particularly
in the region predicted to form intimate contacts with the
mature growth factor domains. Substituting mGDF9 res-
idues across this region into the hGDF9 prodomain in-
creased expression 8-fold, indicating that the hGDF9
prodomain is designed to limit mature growth factor
expression.
TGF-1 is secreted in a latent form because of two
majoradaptionswithin itsprodomain:1) cysteine residues
(Cys223 and Cys225) within the bowtie region, which co-
valently link the two prodomain chains; and 2) fastener
residues (Lys27, Tyr74, Tyr75, Ala76, and Arg238), which
intimately connect the straight-jacket and arm regions of
the prodomains (25). Mutation of these latency-confer-
ring residues results in the spontaneous activation of
TGF-1 (25, 34). Interestingly, the two prodomain chains
of hGDF9 are not covalently linked, nor do they show
conservation of fastener residues, suggesting that a sepa-
rate mechanism confers latency to hGDF9. In support,
linking the prodomain of active mGDF9 to the mature
domain of hGDF9 was insufficient to restore biological
activity.
The mature domains of mouse and human GDF9 are
90% identical, with most differences occurring at the dis-
ordered N terminus. Within the structurally ordered re-
gions of hGDF9, only four amino acids are not conserved
(Gly391, Ser412, Ala422, and Lys450). Of these, Gly391 was
of most interest because it is located in the prehelix loop,
a region of other TGF- ligands critical for type I receptor
interactions (26, 27). Significantly, mutation of the cor-
responding residues in BMP4 (Ala346Val) and GDF5
(Arg438Leu) cause the diseases nonsyndromic orofacial
cleft type 11 and multiple synostoses syndrome type 2,
respectively (35, 36). In addition, Gly391 is present in all
species except mouse, rat, hamster, greater galago, and
possum, in which it is substituted with an arginine. Incor-
poration of an arginine at position 391 resulted in an
hGDF9 variant that was active in two separate bioassays,
indicating that Gly391 is necessary and sufficient to confer
latency to hGDF9. Gly391 reduces the affinity of hGDF9
for its signaling receptors (37), ensuring that it remains
noncovalently associated with its prodomain. Because
Gly391 is conserved inmost other species (Fig. 6), it is likely
that GDF9 latency is a common phenomenon. In support,
ovine GDF9 is also secreted in a latent form (14).
For latent TGF- ligands to signal via specific com-
plexes of type I and type II serine/threonine kinase recep-
tors, they must be separated from their prodomains. The
mechanism of activation differs for individual ligands ac-
cording to prodomain affinity, cell type, and context, but
all known activating mechanisms directly target prodo-
mains (38). One common mechanism of activation is via
members of the BMP1/tolloid (TLD) family of extracel-
lular metalloproteases. Wolfman et al. (24) showed that
BMP1can cleave themyostatin prodomainbetweenArg98
and Asp99, just upstream of the fastener, and thereby ac-
tivate latent myostatin. Mice carrying a myostatin
(Asp99Ala) point mutation, which renders the prodomain
protease resistant, exhibit increases inmusclemass similar
to those seen in mice lacking myostatin (39, 40). GDF11,
which plays important roles in anterior-posterior pattern-
ing of the axial skeleton (41) and the inhibition of neuro-
genesis (42), also requires activation by BMP1/TLD pro-
teases both in vitro and in vivo (21, 43). In addition,
FIG. 7. hGDF9 (Gly391Arg) stimulates granulosa cell proliferation.
Mural granulosa cells were cultured with increasing concentrations
(3.9–500 ng/ml) of recombinant mGDF9 (f), IMAC-purified hGDF9
(E), or IMAC-purified hGDF9 (Gly391Arg) (F). After 24 h of culture, the
labeled thymidine incorporated into cells was counted. Points are
mean  SEM from duplicate wells from a representative experiment.
The experiment was performed three times.
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BMP1/TLDproteases can activate the latent BMP10 com-
plex (44) and cleave latent TGF- binding proteins at two
sites to facilitate the subsequent activation of TGF-1
(45). A recent study demonstrated that BMP1 is expressed
by granulosa cells at all stages of follicular development
(46), identifying this protease as a potential activator of
oocyte-secreted hGDF9. Further studies are required to
determinewhether BMP1 can cleave and activate hGDF9.
The differences in expression and bioactivity of GDF9
across species have implications for the broader TGF-
superfamily. Previous studies have shown striking differ-
ences in the reproductive phenotypes of BMP15 knockout
mice (subfertility) and BMP15-mutant sheep (sterility)
and have identified defects in production of mBMP15 as
a likely cause (3, 29, 47, 48). However, murine and ovine
BMP15 also differ at the residue corresponding to Gly391
in hGDF9 (Pro in mBMP15; His in ovine BMP15), sug-
gesting that BMP15bioactivity could also be differentially
modulated across species. Sequence analysis indicates that
other TGF- ligands with reproductive roles (e.g. anti-
Mullerian hormone, inhibin-, BMP8B) also have signif-
icant differences in the structurally important regions of
their pro- and mature domains. Further studies are re-
quired to determine whether these differences contribute
to the variation observed in follicular development, ovu-
lation rate, and fecundity between mammals.
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